## Konica Minolta, Inc. <br> $1^{\text {st }}$ Quarter/FY2023 ending in March 2024 <br> Consolidated Financial Results

Toshimitsu Taiko
President and CEO

Three months: April 1, 2023 - June 30, 2023

- Announced on August 1, 2023 -


## FY2023 Q1 Result

- Year on year:
> Office and production print revenue and profit increased, while revenue and profit decreased in sensing. Losses narrowed on a company-wide basis due to revenue and profit growth.
- Versus plan:
> Overall, results slightly exceeded the company's expectations.


## Medium-Term Business Plan Progress

- Business selection and concentration
> Non-focused business: In addition to IPO preparations, began considering specific measures to utilize third-party capital
> Direction-changing business: Assessed profitability of and formulated policies for each business
- Reinforcement of financial foundation
> Operating CF returned to profitability ( $+¥ 17.9$ billion YoY) due to reduction of working capital

FY2023 Q1 performance OVERVIEW


## FY2023 Q1 Performance | Summary

150

## Revenue

- Increased revenue YoY for company overall
- Increase: Digital Workplace, Professional Print, Healthcare Decrease: Industry


## Profit/cash flow

- Business contribution profit* \& operating profit: Losses narrowed due to gross profit growth and SG\&A containment
- FCF: Improvement due to better operating CF
[¥ billions]

|  | $\begin{gathered} \text { FY23 } \\ \text { Q1 } \end{gathered}$ | vs FY22 |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | FY22 Q1 | YoY | w/o FOREX |
| Revenue | 266.4 | 247.8 | +7\% | +3\% |
| Gross Profit | 111.9 | 104.8 | +7\% | +2\% |
| Gross Profit ratio | 42.0\% | 42.3\% | -0.3pt |  |
| SG \& A | 116.0 | 110.7 | +5\% | +1\% |
| Business Contribution Profit * | -4.1 | -5.9 | - |  |
| Operating Profit | -4.4 | -11.0 | - |  |
| Profit attributable to owners of the Company | -5.6 | -8.7 | - |  |
| FCF | -10.8 | -24.9 | - |  |
| FOREX [Yen] |  |  |  |  |
| USD | 137.37 | 129.57 | +7.80 |  |
| EUR | 149.47 | 138.12 | +11.35 |  |

[^0]FY2023 Q1 Performance \| Revenue \& Profit by Segment
[ $¥$ billions]

| Revenue | FY23 Q1 | vs FY22 |  |  |
| :--- | ---: | ---: | ---: | ---: |
|  |  | 143.3 | FY22 Q1 | YoY |
|  |  |  |  |  |
| Digital Workplace | 60.2 | 128.9 | $+11 \%$ | $+5 \%$ |
| Profe ssional Print | 29.3 | 55.1 | $+9 \%$ | $+5 \%$ |
| Healthcare | 33.2 | 28.7 | $+2 \%$ | $-1 \%$ |
| Industry *1 | 0.4 | 34.9 | $-5 \%$ | $-8 \%$ |
| Corporate, etc. | 266.4 | 0.3 | $+34 \%$ | $+34 \%$ |
| Company overall |  | 247.8 | $+7 \%$ | $+3 \%$ |


| Business Contribution Profit | FY23 Q1 rate |  | vs FY22 After adjustment for head-office expenses *2 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | FY22 Q1 | YoY | w/o FOREX |
| Digital Workplace | 2.4 | 2\% | -0.2 | - | - |
| Professional Print | 0.8 | 1\% | 0.2 | +304\% | +41\% |
| Healthcare | -3.2 | - | -5.7 | - | - |
| Industry * 1 | 2.6 | 8\% | 7.0 | -63\% | -67\% |
| Corporate, etc. | -6.6 | - | -7.2 | - | - |
| Company overall | -4.1 | - | -5.9 | - | - |


| Operating Profit | FY23 Q1 |  | vs FY22 After adjustment for head-office expenses *2 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | FY22 Q1 | YoY | w/o FOREX |
| Digital Workplace | 2.0 | 1\% | -4.3 | - | - |
| Professional Print | 0.9 | 2\% | -0.1 | - | - |
| Healthcare | -3.4 | - | -6.3 | - | - |
| Industry *1 | 2.7 | 8\% | 7.0 | -62\% | -66\% |
| Corporate, etc. | -6.6 | - | -7.3 | - | - |
| Company overall | -4.4 | - | -11.0 | - | - |

FY2023 Q1 Performance | Factors of Increase/Decrease of Operating Profit

150

## FY22 <br> Q1

FY23
Other income



# FY2023 Q1 Performance | Business Trends of Industry 



FY2023 Q1 Performance | Business Trends of Healthcare


FY2023 Q1 Performance | Business Trends of Professional Print


FY2023 Q1 Performance | Business Trends of Digital Workplace


## MEDIUM-TERM BUSINESS PLAN PROGRESS



# Medium-Term Business Plan Progress | Non-focused business and Direction-changing business 

Business Contribution
Profit transition
Result Forecast

Progress of business selection and concentration

## Non-focused business

| - Received notice from INCJ, Ltd. on July $3^{\text {rd }}$ for exercise of put |  |
| :--- | :--- |
| Precision | option |
| Medicine | In addition to IPO preparations, began considering specific <br> measures to utilize third-party capital |

## Direction-changing business

| DW-DX | Review the IT management service (IMS business*), a <br> business with limited synergy with Office unit and that has <br> limited development resources, for each region from a best- <br> owner perspective |
| :---: | :--- |
| Imaging-IoT | - Improving profitability by narrowing focus areas of imaging <br> analysis solution <br> (Focusing on outdoor/thermal utilization areas in Europe and <br> the U.S.) |

Medium-Term Business Plan Progress | Non-focused business and Direction-changing business | Milestone


Cost Structure Reform | Progress in B/S Improvement

| Target | - Total asset turnover of 1.0 x at the end of FY2025 |
| :---: | :--- |
| FY23 Q1 | - Total assets: Reduced by $¥ 34.9$ billion ( $¥ 97.8$ billion reduction excluding foreign exchange <br> impact) due to reduction of CAPEX, working capital, etc. <br> Results <br> - Inventories: Increased $¥ 3.5$ billion ( $¥ 7.2$ billion reduction excluding foreign exchange impact) |



Reinforcement of Financial Foundation | Inventories and Operating Cash Flow


## FY2023 Earnings Forecast | Summary

- Forecasts are unchanged from the beginning of this fiscal year; presumed exchange rates for USD/EUR are also unchanged
- Operating profit remains unchanged considering economic uncertainty, although the USD will be a negative factor and the EUR and CNY will be favorable factors

*1 Depreciation and amortization expenses : IFRS16 right-of-use assets amortization expenses not included.
*2 FOREX Sensitivity: FOREX impact at $¥ 1$ change (annual)


## SUSTAINABILITY INITIATIVES



## Designating "Konica Minolta Group Safety Day" and Promoting Disaster Prevention Initiative

- Konica Minolta has designated July 6 as "Group Safety Day" to remember the reflections and lessons from the fire and explosion accidents at the Tatsuno Factory in 2021, and to promote disaster prevention efforts.
- On the Group Safety Day, executives visit manufacturing sites and provide an opportunity to consider general safety initiatives to enhance safety and security in the workplace together, reviewing with on-site employees the workplace environment, disaster risks, and safety initiatives.

24 executives visited manufacturing sites in Japan on July 6, 2023


Executives' visit (Tatsuno Factory of Konica Minolta Supplies Manufacturing)


Tree-planting ceremony
(Tatsuno Factory of Konica Minolta Supplies Manufacturing)


On-site talks between executives and employees (Seishin Factory of Konica Minolta Supplies Manufacturing)

- Konica Minolta has fundamentally revised the Group Safety and Health Management Regulations to ensure reliable implementation of risk assessments, which are an important measure for preventing disasters. We are also strengthening efforts in disaster prevention, including information sharing beyond company boundaries at domestic and overseas production sites.


## Achieved 100\% renewable electricity at all overseas MFP manufacturing sites

- Achieved 100\% renewable electricity at MFP manufacturing site in Malaysia
- With the MFP manufacturing sites in China having already achieved 100\% renewable electricity, achievement at the Malaysian site marks 100\% renewable electricity at all overseas MFP manufacturing sites
- Achievement was made possible by installing solar power generation systems at each site, among other factors


Received the Chester F. Carlson Award 2023 for outstanding contribution in the field of electrophotographic process technology

- Awarded by the Society for Imaging Science and Technology (IS\&T), an international imaging society, to Konica Minolta employee Natsuko Minegishi
- This is an internationally prestigious award, presented each year to one researcher who made an outstanding achievement in science or technology related to electrophotography

Dr. Natsuko Minegishi Advanced Core Technology Center, Technology Development Headquarters, Konica Minolta, Inc.


Pride month: carried out DEI programs globally

- Carried out DEI programs globally (including Japan) on June 22
- [Global Program] Five Group employees talked about "working as we are" and "a sense of belonging in the workplace" and shared their experiences with Group employees in 22 countries (held online)


Named to all ESG indexes adopted by GPIF for seven consecutive years, and included in the FTSE4Good Index Series for 20 consecutive years

- Named to all of the six responsible investment (RI) indexes adopted by Japan's Government Pension Investment Fund (GPIF)
- This is the seventh consecutive year for Konica Minolta to be listed on all of these ESG indexes since the GPIF first adopted them
- Also included in the FTSE4Good Index Series for 20 consecutive years
$\mathbf{2 0 2 3}$ CONSTITUENT MSCI JAPAN
ESG SELECT LEADERS INDEX

2023 CONSTITUENT MSCI JAPAN EMPOWERING WOMEN INDEX (WIN)

- Mid-October: Briefing session on strengthening businesses (Industry)
- Mid-December: Konica Minolta Day, sustainability briefing session


| Before March 31, 2023 |  |
| :---: | :---: |
| Digital Workplace Business | $\begin{aligned} & \text { Office(OP) } \\ & \text { DW-DX(DW-DX) } \end{aligned}$ |
| Professional Print Business | - Production print(PP) <br> - Industrial print(IP) <br> - Marketing services(MS) |
| Healthcare Business | ```■ Healthcare(HC) Precision medicine(APM)``` |
| Industry Business | Sensing |
|  | ■ Measuring instruments(MI) |
|  | Materials and components |
|  | ■ Performance materials(PM) <br> ■ Optical components(OC) <br> ■ IJ components(IJ) |
|  | Imaging-IoT solutions |
|  | ■ Imaging-IoT solutions(IIS) <br> ■ Visual solutions(VS) |
| Corporate, etc., QOL |  |

## After April 1, 2023

| Digital Workplace Business | $\begin{aligned} & ■ \text { Office(OP) } \\ & \text { DW-DX(DW-DX) } \end{aligned}$ |
| :---: | :---: |
| Professional Print Business | - Production print(PP) <br> ■ Industrial print(IP) <br> ■ Marketing services(MS) |
| Healthcare Business | - Healthcare(HC) <br> ■ Precision medicine(APM) |
| Industry Business | - Sensing(SE) <br> - Performance materials(PM) <br> ■ Optical components(OC) <br> - IJ components(IJ) <br> ■ Imaging-IoT solutions(IIS) <br> ■ Visual solutions(VS) |
| Corporate, etc., QOL |  |

150

## APPENDIX

Some of the materials that had been disclosed on this presentation slides have been changed to disclosure on the website. You can download and check it from below.
https://www.konicaminolta.com/shared/changeable/investors/include/fr/pdf/2024/2024_1q_ presentation_supplementary.xlsx

## FY2023 Earning Forecast | Factors of Increase/ Decrease of

 Operating Profit- Special factors in FY22: Shedding of air freight expenses, logistics expenses, structural reform expenses, shedding of order backlog
- FY23 forecast: Increase in sales volume, price adjustment, increase in costs


FY2023 Earning Forecast | Revenue, Business contribution profit and Operating profit by segments

| Revenue | FY23 <br> Forecast | vs FY22 |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | FY22 Result | Change | Change rate |
| Digital Workplace | 590.0 | 600.3 | -10.3 | -2\% |
| Professional Print | 255.0 | 252.6 | +2.4 | +1\% |
| Healthcare | 140.0 | 137.8 | +2.2 | +2\% |
| Industry ${ }^{1}$ | 154.0 | 137.5 | +16.5 | +12\% |
| Corporate, etc. | 1.0 | 2.1 | -1.1 | -53\% |
| Company overall | 1,140.0 | 1,130.4 | +9.6 | +1\% |


| Business contribution profit | FY23 <br> Forecast | Ratio | vs FY22 After adjustment for head-office expenses |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | FY22 Resu |  | Change | Change rate |
| Digital Workplace | 20.0 | 3\% | 30.7 | 5\% | -10.7 | -35\% |
| Professional Print | 11.5 | 5\% | 15.1 | 6\% | -3.6 | -24\% |
| Healthcare | -3.5 | - | -7.0 | - | +3.5 | - |
| Industry *1 | 22.0 | 14\% | 21.7 | 16\% | +0.3 | +1\% |
| Corporate, etc. | -26.0 | - | -30.7 | - | +4.7 | - |
| Company overall | 24.0 | 2\% | 29.7 | 3\% | -5.7 | -19\% |


| Operating profit | FY23 <br> Forecast | Ratio | vs FY22 After adjustment for head-office expenses |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | FY22 Res |  | Change | Change rate |
| Digital Workplace | 17.0 | 3\% | 24.4 | 4\% | -7.4 | -30\% |
| Professional Print | 11.0 | 4\% | 14.4 | 6\% | -3.4 | -24\% |
| Healthcare | -4.0 | - | -8.0 | - | +4.0 | - |
| Industry *1 | 21.0 | 14\% | 21.6 | 16\% | -0.6 | -3\% |
| Corporate, etc. | -27.0 | - | -30.9 | - | +3.9 | - |
| Company overall | 18.0 | 2\% | 21.5 | 2\% | -3.5 | -16\% |

 Corporate, etc. in this material

## Analysis of Increase/ Decrease of Operating Profit

[¥ billions]

| Comparison of Y on Y <br> FY23/Q1 vs. FY22/Q1 | Digital Workplace | Professional Print | Healthcare | Industry | Corporate, etc. | Company overall |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| [Operating Profit] |  |  |  |  |  |  |
| FOREX impact | +0.4 | +0.5 | - 0.2 | +0.3 | - 0.1 | +0.9 |
| Sales volume change, and other | +2.2 | +0.6 | +1.9 | - 4.0 | +0.1 | +0.7 |
| Price adjustment | +1.1 | +0.3 | +0.0 | +0.3 | +0.0 | +1.7 |
| SG\&A expenses | - 1.2 | - 0.8 | +0.7 | - 0.9 | +0.6 | - 1.6 |
| Other income and expenses | +3.7 | +0.4 | +0.5 | +0.1 | +0.1 | +4.8 |
| Total | +6.2 | +1.0 | +2.9 | -4.2 | +0.7 | +6.6 |

Eliminated excess order backlog to normal levels.
Indexed with FY2019 Q1 as 100

| Offlce |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\qquad$ |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 90\% <br> 80\% <br> 70\% <br> 60\% | $0 \%$ $59 \%$ |  | 90\% $85 \%$ | 84\% |  | 95\% <br> 81\% $53{ }^{5}$ |  | $\begin{aligned} & 95 \% \\ & \text { 93\% } \\ & 85 \% \\ & \frac{85 \%}{} \end{aligned}$ | 94\% <br> 86\% <br> 85\% <br> 1\% |  | $86 \%$ $84 \%$, $78 \%$ d (orde -hard -hard | basis) <br> order ba | $94 \%$ $-89 \%$ $82 \%$ $81 \%$ <br> sis) |
| 50\% | Q1 | $\begin{aligned} & \text { Q2 } \\ & \quad \mathrm{FY} 2 \end{aligned}$ | $\begin{gathered} \text { Q3 } \\ 20 \end{gathered}$ | Q4 |  | Q2 FY | $\begin{aligned} & \text { Q3 } \\ & 21 \end{aligned}$ | Q4 |  | Q2 $\mathrm{FY}$ | $\begin{gathered} \text { Q3 } \\ 22 \end{gathered}$ |  | $\begin{gathered} \text { Q1 } \\ \text { FY23 } \end{gathered}$ |
| Japan | 85\% | 90\% | 94\% | 92\% | 92\% | 87\% | 91\% | 89\% | 89\% | 87\% | 89\% | 89\% | 88\% |
| U.S. | 62\% | 73\% | 78\% | 81\% | 77\% | 75\% | 74\% | 82\% | 77\% | 80\% | 81\% | 82\% | 71\% |
| Europe | 66\% | 82\% | 83\% | 78\% | 83\% | 82\% | 77\% | 82\% | 87\% | 82\% | 78\% | 87\% | 82\% |
| China | 107\% | 105\% | 115\% | 140\% | 109\% | 111\% | 75\% | 110\% | 114\% | 107\% | 104\% | 127\% | 108\% |
| India | 52\% | 68\% | 98\% | 113\% | 73\% | 103\% | 127\% | 108\% | 143\% | 128\% | 159\% | 144\% | 180\% |
| Overall | 69\% | 80\% | 85\% | 84\% | 84\% | 81\% | 81\% | 85\% | 85\% | 85\% | 86\% | 87\% | 82\% | Production Print



## Revenue and KPI Trends of Genetic Testing and Drug Discovery Support Business



## Invicro:

Fluctuation in revenue and total backlog
Total backlog
(Index)
Revenue
(Index)

150

50

0

Indexed with FY2019 Q1 as 100 / Revenue is JPY basis.
*Before reduction of recoverable amount of accounts receivable and revenue
**After reflection of recoverable amount of accounts receivable and revenue
[ $¥$ billions]

|  | FY23 Q1 | [¥ billions] |  |
| :---: | :---: | :---: | :---: |
|  |  | vs FY22 |  |
|  |  | FY22 Q1 | YoY |
| Revenue | 266.4 | 247.8 | +7\% |
| Gross Profit | 111.9 | 104.8 | +7\% |
| Gross Profit ratio | 42.0\% | 42.3\% | - 0.3pt |
| SG \& A | 116.0 | 110.7 | +5\% |
| Business Contribution Profit | -4.1 | -5.9 | - |
| Other income and costs | -0.3 | -5.1 | - |
| Operating Profit | -4.4 | -11.0 | - |
| Operating Profit ratio | - | - | - |
| Finance income and costs | -1.3 | 3.5 | - |
| Profit before tax | -5.8 | -7.6 | - |
| Profit before tax ratio | - | - | - |
| Profit attributable to owners of the Company | -5.6 | -8.7 | - |
| Profit attributable to owners of the Company ratio | - | - | - |
| EPS [Yen] | -11.27 | -17.69 |  |
| CAPEX | 7.8 | 8.4 |  |
| Depreciation and Amortization Expenses | 13.4 | 13.8 |  |
| R\&D expenses | 16.1 | 15.3 |  |
| FCF | -10.8 | -24.9 |  |
| Investment and lending | - | 0.9 |  |
| FOREX [Yen] USD | 137.37 | 129.57 | +7.80 |
| EUR | 149.47 | 138.12 | +11.35 |


|  | [ $¥$ billions] |  |  |
| :---: | :---: | :---: | :---: |
|  | FY23 Q1 | vs FY22 |  |
|  |  | FY22 Q1 | YoY |
| SG\&A |  |  |  |
| Selling expenses - variable | 11.0 | 12.7 | -1.7 |
| R\&D expenses | 16.1 | 15.3 | +0.8 |
| Personnel expenses | 56.8 | 52.2 | +4.6 |
| Others | 32.0 | 30.4 | +1.6 |
| SG\&A total | 116.0 | 110.7 | +5.3 |
| * FOREX impact: | +4.4bn. | (Actual: + | bn.) |
| Other income: |  |  |  |
| Insurance income | 0.0 | 1.0 | -0.9 |
| Other income | 1.4 | 0.8 | +0.6 |
| Other income total | 1.5 | 1.8 | -0.3 |
| Other expenses |  |  |  |
| Business structure improvement costs | 0.6 | 3.5 | -2.9 |
| Settlement payments | - | 1.6 | -1.6 |
| Other expenses | 1.2 | 1.7 | -0.6 |
| Other expenses total | 1.8 | 6.8 | -5.1 |
| Finance income/loss: |  |  |  |
| Interest income/Dividends received/Interest expense | -2.4 | -1.0 | -1.4 |
| Foreign exchange gain/loss (net) | 1.5 | 4.2 | -2.7 |
| Others | -0.4 | 0.2 | -0.6 |
| Finance income/loss, net | -1.3 | 3.5 | -4.7 |

[ $¥$ billions]

|  | FY21 Q1 | FY22 Q1 | FY23 Q1 |
| :--- | ---: | ---: | ---: | ---: |
| Profit (loss) before tax | 2.5 | -7.6 | -5.8 |
| Depreciation and amortization expenses | 19.0 | 18.8 | 18.6 |
| (Increase) decrease in trade and other receivables | 14.7 | 10.4 | 24.5 |
| (Increase) decrease in inventories | 5.3 | -16.4 | 9.4 |
| Increase (decrease) in trade and other payables | -14.7 | -3.2 | -31.3 |
| Others | -17.8 | -19.7 | -15.2 |
| Cash flows from operating activities | $\mathbf{9 . 1}$ | $\mathbf{- 1 7 . 7}$ | $\mathbf{0 . 2}$ |
| Purchase of property, plant and equipment | -9.3 | -4.9 | -5.2 |
| Purchase of intangible assets | -4.4 | -4.6 | -4.3 |
| Purchase of investments in subsidiaries | 0.0 | -0.2 | $\mathbf{- 1 . 0}$ |
| Others | 1.8 | 2.5 | -0.5 |
| Net cash provided by (used in) investing activities | $\mathbf{- 1 1 . 9}$ | $\mathbf{- 7 . 2}$ | $\mathbf{- 1 1 . 1}$ |
| Free cash flows | $\mathbf{- 2 . 8}$ | $\mathbf{- 2 4 . 9}$ | $\mathbf{- 1 0 . 8}$ |

# Consolidated Statements of Financial Position 

[ $¥$ billions]
[ $¥$ billions]

|  | Mar 2022 | Mar 2023 | Jun 2023 |
| :--- | ---: | ---: | ---: | ---: |
| Cash and cash equivalents | 117.7 | 180.6 | 109.8 |
| Trade and other receivables | 280.2 | 313.5 | 314.7 |
| Inventories | 185.7 | 242.1 | 245.6 |
| Other current assets | 35.3 | 41.4 | 48.5 |
| Total current assets | $\mathbf{6 1 8 . 9}$ | $\mathbf{7 7 7 . 6}$ | $\mathbf{7 1 8 . 8}$ |
| Property, plant and equipment | 287.7 | 289.1 | 295.2 |
| Goodwill and intangible asseets | 354.1 | 258.9 | 272.8 |
| Othe non-current assets | 77.4 | 88.2 | 92.0 |
| Total non-current assets | $\mathbf{7 1 9 . 3}$ | $\mathbf{6 3 6 . 2}$ | $\mathbf{6 6 0 . 1}$ |
| Total assets | $\mathbf{1 , 3 3 8 . 1}$ | $\mathbf{1 , 4 1 3 . 8}$ | $\mathbf{1 , 3 7 8 . 8}$ |


|  | Mar 2022 | Mar 2023 | Jun 2023 |
| :--- | ---: | ---: | ---: | ---: |
| Trade and other payables | 182.1 | 200.5 | 180.8 |
| Bonds and borrowings | 354.3 | 469.1 | 414.5 |
| Lease liabilities | 94.3 | 99.2 | 104.3 |
| Othe liabilities | 145.9 | 145.1 | 159.5 |
| Total liabilities | $\mathbf{7 7 6 . 6}$ | $\mathbf{9 1 3 . 9}$ | $\mathbf{8 5 9 . 1}$ |
| Equity attributable to owners of the Company | 549.8 | 487.4 | 506.9 |
| Non-controlling interests | 11.7 | 12.5 | 12.8 |
| Total equity | $\mathbf{5 6 1 . 5}$ | $\mathbf{4 9 9 . 9}$ | $\mathbf{5 1 9 . 7}$ |
| Total liabilities and equity | $\mathbf{1 , 3 3 8 . 1}$ | $\mathbf{1 , 4 1 3 . 8}$ | $\mathbf{1 , 3 7 8 . 8}$ |


|  | Mar 2022 | Mar 2023 | Jun 2023 |
| :--- | ---: | ---: | ---: |
| Equity ratio (\%) | 41.1 | 34.5 | 36.8 |
| Equity ratio for company rating (\%) | 44.8 | 37.9 | 40.3 |
| D/E ratio | 0.82 | 1.17 | 1.02 |

[FOREX: $¥]$
[Impact, Sensitivity : $¥$ billions]

|  | FY22 | FY23 | YoY Impact |  | FOREX Sensitivity*2 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 3M | 3M | Revenue | OP | Revenue | OP |
| USD | 129.57 | 137.37 | +5.9 | - 0.5 | +3.2 | - 0.3 |
| EUR | 138.12 | 149.47 | +4.4 | +1.3 | +1.8 | +0.6 |
| GBP | 162.96 | 171.91 | +0.6 | +0.0 | +0.3 | +0.1 |
| European Currency*1 | - | - | +5.5 | +1.3 | +2.6 | +0.9 |
| CNY | 19.58 | 19.56 | - 0.0 | +0.2 | +3.4 | +1.0 |
| Other | - | - | +0.4 | - 0.0 | - | - |
| Exchange contract effect | - | - | - | +0.0 | - | - |
| Total | - | - | +11.8 | +0.9 | - | - |

FY2023 Q1 Performance \| Revenue and Profit by Segment YoY

|  |  | VS FY22 |  |  |
| :--- | ---: | ---: | ---: | ---: |
| Revenue |  |  |  |  |
|  |  | FY22 Q1 | YoY | w/o FOREX |
| Digital Workplace | 143.3 | 128.9 | $+11 \%$ | $+5 \%$ |
| Professional Print | 60.2 | 55.1 | $+9 \%$ | $+5 \%$ |
| Healthcare | 29.3 | 28.7 | $+2 \%$ | $-1 \%$ |
| Industry *1 | 33.2 | 34.9 | $-5 \%$ | $-8 \%$ |
| Corporate, etc. | 0.4 | 0.3 | $+34 \%$ | $+34 \%$ |
| Company overall | 266.4 | 247.8 | $+7 \%$ | $+3 \%$ |

[¥ billions]

| Business Contribution Profit | FY23 Q1 |  | vs FY22 |  |  | vs FY22 After adjustment for head-office expenses |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | FY22 Q1 | YoY | w/o FOREX | FY22 Q1 | YoY | w/o FOREX |
| Digital Workplace | 2.4 | 2\% | -3.5 | - | - | -0.2 | - | - |
| Professional Print | 0.8 | 1\% | 1.2 | -33\% | -77\% | 0.2 | +304\% | +41\% |
| Healthcare | -3.2 | - | -5.9 | - | - | -5.7 | - | - |
| Industry *1 | 2.6 | 8\% | 6.2 | -59\% | -63\% | 7.0 | -63\% | -67\% |
| Corporate, etc. | -6.6 | - | -4.0 | - | - | -7.2 | - | - |
| Company overall | -4.1 | - | -5.9 | - | - | -5.9 | - |  |


| Operating Profit/OPM | FY23 Q1 |  | vs FY22 |  |  | vs FY22 After adjustment for head-office expenses |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | FY22 Q1 | YoY | w/o FOREX | FY22 Q1 | YoY | w/o FOREX |
| Digital Workplace | 2.0 | 1\% | -7.6 | - | - | -4.3 |  |  |
| Professional Print | 0.9 | 2\% | 0.9 | +1\% | -55\% | -0.1 |  |  |
| Healthcare | -3.4 | - | -6.5 | - | - | -6.3 | - |  |
| Industry *1 | 2.7 | 8\% | 6.2 | -57\% | -62\% | 7.0 | -62\% | -66\% |
| Corporate, etc. | -6.6 | - | -4.1 | - | - | -7.3 | - |  |
| Company overall | -4.4 | - | -11.0 | - | - | -11.0 | - |  |

Quarterly Financial Results by Segments: Revenue
[ $¥$ billions]

| [Revenue] | FY22 |  |  |  |  | $\begin{gathered} \text { FY23 } \\ \text { Q1 } \\ \hline \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | Total |  |
| Digital Workplace | 128.9 | 149.6 | 158.7 | 163.1 | 600.3 | 143.3 |
| Office | 110.9 | 129.0 | 137.7 | 141.6 | 519.1 | 122.6 |
| DW-DX | 18.0 | 20.6 | 20.9 | 21.6 | 81.1 | 20.7 |
| Professional Print | 55.1 | 64.8 | 65.1 | 67.7 | 252.6 | 60.2 |
| Production print | 35.5 | 41.7 | 42.9 | 41.9 | 161.9 | 37.7 |
| Industrial print | 6.0 | 8.2 | 7.2 | 11.0 | 32.3 | 7.7 |
| Marketing services | 13.6 | 14.9 | 15.1 | 14.8 | 58.4 | 14.8 |
| Healthcare | 28.7 | 35.3 | 32.9 | 40.9 | 137.8 | 29.3 |
| Medical imaging | 19.1 | 25.0 | 21.3 | 29.1 | 94.6 | 18.0 |
| Precision medicine | 9.5 | 10.3 | 11.6 | 11.8 | 43.3 | 11.3 |
| Industry | 34.9 | 32.5 | 33.1 | 36.6 | 137.1 | 33.2 |
| Sensing | 13.5 | 11.4 | 11.3 | 10.8 | 46.9 | 9.1 |
| Performance materials | 11.3 | 8.0 | 8.3 | 11.6 | 39.2 | 11.4 |
| IJ components | 3.7 | 4.2 | 4.7 | 4.5 | 17.1 | 4.5 |
| Optical components | 3.6 | 5.4 | 5.4 | 5.3 | 19.8 | 4.7 |
| Imaging-IoT solutions | 2.0 | 2.5 | 2.6 | 2.7 | 9.8 | 2.7 |
| Visual solutions | 0.8 | 0.9 | 0.9 | 1.8 | 4.3 | 0.8 |
| Corporate, etc. | 0.3 | 0.7 | 0.5 | 1.0 | 2.6 | 0.4 |
| Company overall | 247.8 | 282.9 | 290.3 | 309.4 | 1130.4 | 266.4 |


| [Business Contribution Profit] |  |  |  |  | [ $¥$ billions] |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY22 |  |  |  |  | FY23 |
|  | Q1 | Q2 | Q3 | Q4 | Total | Q1 |
| Digital Workplace | -0.2 | 7.4 | 9.4 | 14.0 | 30.7 | 2.4 |
| Professional Print | 0.2 | 3.6 | 5.5 | 5.7 | 15.1 | 0.8 |
| Healthcare | -5.7 | -2.1 | -0.4 | 1.1 | -7.0 | -3.2 |
| Industry | 7.0 | 5.2 | 4.1 | 5.5 | 21.7 | 2.6 |
| Corporate, etc. | -7.2 | -7.6 | -8.4 | -7.5 | -30.7 | -6.6 |
| Company overall | -5.9 | 6.7 | 10.2 | 18.8 | 29.7 | -4.1 |


|  | Q1 |  | Q2 | Q3 | Q4 | Total | Q1 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| [Operating Profit] | -4.3 | 7.0 | 8.0 | 10.8 | $\mathbf{2 1 . 5}$ | 2.0 |  |
| Digital Workplace | -0.1 | 3.6 | 5.4 | 4.7 | $\mathbf{1 3 . 6}$ | 0.9 |  |
| Professional Print | -6.3 | -2.3 | -0.4 | -102.5 | $\mathbf{- 1 1 1 . 5}$ | -3.4 |  |
| Healthcare | 7.0 | 5.2 | 4.0 | -2.6 | $\mathbf{1 3 . 5}$ | 2.7 |  |
| Industry | -7.3 | -7.6 | -8.4 | -8.8 | $\mathbf{- 3 2 . 1}$ | -6.6 |  |
| Corporate, etc. | -11.0 | 5.9 | 8.5 | -98.5 | $\mathbf{- 9 5 . 1}$ | -4.4 |  |
| Company overall |  |  |  |  |  |  |  |

## Glossary

- MFP (Multi Functional Peripheral) speed segment: Digital Workplace Business Seg. 1 to 20ppm, Seg. 2 21-30ppm, Seg. 3 31-40ppm, Seg. 4 41-69ppm, Seg. $570 \sim p p m$ (A4 vertical, minute speed)
- Color production print machine segments: Professional Print Business

ELPP (Entry Light Production Print) Monthly printing volume: 1-0.3 million sheets for low-priced products mainly for large companies' centralized printing rooms
LPP (Light Production Print) Monthly printing volume: 0.1-0.3 million sheets for commercial printing
MPP (Mid Production Print) Monthly printing volume: 30-1 million sheets for commercial printing
HPP (Heavy Production Print) Monthly printing volume:1 million sheets or more for commercial printing

- RNA (ribonucleic acid) testing: Healthcare Business

Testing to identify changes in mRNA structure in the primary transcript of DNA(deoxyribonucleic acid). Analysis of transcript mRNA can provide more detailed test results on DNA mutations that used to be considered of undetermined clinical significance in conventional DNA testing.

- CARE Program (Comprehensive Assessment, Risk \& Education): Healthcare Business

Program to provide total support for effective pick-up and genetic diagnostics of the high-risk group of genetic breast cancer.

- GenMineTOP cancer genome profiling system: Healthcare Business

This system, developed together with the University of Tokyo and the National Cancer Center Research Institute, analyzes genes in tumor tissue. This system is unique in that it analyzes not only DNA, but also RNA, and analyzes the DNA of noncancerous cells as well as the tumor tissue.

- FORXAI : Imaging-IoT Solutions Business

FORXAI is an imaging IoT platform that accelerates digital transformation of society together with customers and partners.


[^1]
[^0]:    *Business contribution profit: Original index of the Company, the profit subtracted sales cost, SG\&A from revenue

[^1]:    Cautionary Statement:
    The forecasts mentioned in this material are the results of estimations based on currently available information, and accordingly, contain risks and uncertainties. The actual results of business performance may sometimes differ from those forecasts due to various factors.

    Remarks:
    Yen amounts are rounded to the nearest 100 million.

